No immunosuppression, can be used during viral vaccination
Good tolerance at the injection site
Long-term slow release, one shot last for seven days
The ceftiofur hydrochloride crystal combined with the new formulation process ensures the slow release of the active ingredient, and the blood concentration of the drug exceeds 90%. The minimum inhibitory concentration of respiratory pathogens is 168 hours (7 days).
Broad spectrum and efficient sterilization, less resistance
It has ideal effects on infections such as Pasteurella multocida, Pasteurella hemolyticus, Actinobacillus pleuropneumoniae, Haemophilus parasuis, Streptococcus, Staphylococcus, Escherichia coli and Salmonella.
Table 1 The minimum inhibitory concentration of Saifeixin in Shandong province
|Bacteria (several isolates from Shandong pig farms)||MIC50(ug/ml)||MIC90(ug/ml)||MIC range(ug/ml)|
The injection site is well tolerated;No adverse reactions have been observed in the injected pigs;No immunosuppression, can be used before and after inoculation of viral vaccine;After the bottle cap is opened, it is still valid when stored at low temperature for 12 weeks.
Tests have shown that Saficin and its similar products are bioequivalent in pigs. The mean area AUC0-∞ under the plasma concentration-time curve was 369.2±123.7 ug/ml and 385.1±118.9 ug/ml, respectively..
It can be seen from Fig. 1 that the average AUC0-∞ area under the blood concentration-time curve of Saifisin and the original drug is 369.2±123.7 ug/ml and 385.1±118.9 ug/ml, respectively, and the relative bioavailability is 97.5%. It can be considered that Safeixin is bioequivalent to the original drug.
Table 2 Comparison of Saifin and similar preparations
|Saifeixin||Common ceftiofur||Imported product|
|Excipient||Imported||Domestic (with impurities)||Imported|
|Formulation process||American emulsification process||No formulation process||Original research process|
|Effective time||168 h||36-72h||168h|
|Injection stimulation||No irritation at the injection site||Strong stimulus||No irritation at the injection site|
|Storage||Unused low temperature for 12 weeks||short time||Unused low temperature for 12 weeks|
Saifeixin's application, case on the farm
A pig farm in Shandong was weaned at 23 days of age. Piglets after weaning showed symptoms of porcine respiratory disease such as rough hair, cough, weight loss, and asthma. The incidence rate was 17%. In the test group, the piglets were injected with Saifeixin on the day of weaning, 0.3 ml per head. The results are as follows:
Table 3. Saifeixin test results
|Items||Control group||Test group||Difference|
|Number of trials||30||51||+21|
|Average weaning weight(kg)||7.18||7.15||-0.03|
|Average weight at day 60(kg)||18.27||20.49||+2.22|
|Total weight gain during nursery(kg)||11.09||13.34||+2.25|
|Average daily weight gain(g/heda)||299.73||360.54||+60.81|
|Survival rate of piglets during cNursery(%)||92||100||-8|
|FCR during nursery||1.62||1.35||-0.27|
One dose only: intramuscular injection at the neck, 5mg/kg body weight, or 1ml/20kg body weight.No more than 2ml per injection site, more than 40kg pigs need more injection sites.
Safeixin medication procedure
For prevention, group health
According to the characteristics of the disease of the farm, it is usually 2 to 3 days before the onset of the disease.
1)7~10 days of age: intramuscular injection 0.2m l/head;
2)Nursery piglets: intramuscular injection 0.3ml/head on weaning day; or intramuscular injection 0.5ml/head 2 weeks after weaning;
3)On PRRS unstable farm: 1 to 2 weeks after weaning, injection of Saifeixin 1ml/20kg body weight.
For individual treatment
When the affected pig is diagnosed as a bacterial infection (or mixed infection) such as streptococcus suis, haemophilus parasuis, actinobacillus pleuropneumoniae or pasteurella multocida, it is immediately injected with 1 ml/20 kg body weight of Safeixin.
Traits: gray to gray yellow translucent suspension
Specification: 50ml: 5g
Withdrawal period: pig 4 days
Package: 50ml/bottle×20 bottles/box
SHANDONG HUACHEN PHARMACEUTICAL CO.,LTD. was established in June 2001 and registered capital is RMB 50 million. It is a modern pharmaceutical enterprise with two subsidiaries, names SHANDONG HUACHEN PHARMACEUTICAL CO.,LTD. and SHANDONG HWATSON BIOCHEM CO., LTD., which specializes in the production of pharmaceutical preparations and raw chemical materials.
HUACHEN PHARMACEUTICAL has a professional production workshop and testing laboratory in China. In 2016, the GMP pharmaceutical preparations workshop was built according to international standards, which passed the GMP Certification of the Ministry of Agriculture and provided a guarantee for the reliable pharmaceutical preparations combining with the strict production management and quality control system.
Providing customers with the higher-quality products has always been the unremitting striving direction for HUACHEN PHARMACEUTICAL CO., LTD. The company introduced the preparations technology, using the higher-quality customized raw materials and the stable imported ingredients to guarantee the quality of veterinary medicine from the source. HUACHEN veterinary drug preparations inherit the quality of brand drugs to achieve the highest level in quality and efficacy. Its bioequivalence is consistent with the imported drugs, which can effectively replace the imported products, and the price has been greatly reduced.
HUACHEN not only produce the high quality products but rely on the professional disease diagnosis and testing center to provide timely and thoughtful service for the majority of breeding enterprises, which solved the problem of after- sales service.
In 2018, HUACHEN has invested RMB 1 billion to build a Pharmaceutical Production Park which covers a total area of more than 34 hectares in the littoral area, creating the research development and manufacturing base for Vitamin B series. On the basis of the existing business trading, the company also involves the generic drugs for human and the innovative drugs.
HUACHEN PHARMACEUTICAL CO., LTD. will become a comprehensive modern pharmaceutical enterprise with international competitiveness in the future